These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 33339298)

  • 1. Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches.
    Boer GA; Holst JJ
    Biology (Basel); 2020 Dec; 9(12):. PubMed ID: 33339298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on incretin hormones.
    Phillips LK; Prins JB
    Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
    Matuszek B; Lenart-Lipińska M; Nowakowski A
    Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists.
    Gasbjerg LS; Bergmann NC; Stensen S; Christensen MB; Rosenkilde MM; Holst JJ; Nauck M; Knop FK
    Peptides; 2020 Mar; 125():170183. PubMed ID: 31693916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin therapy in feline diabetes mellitus - A review of the current state of research.
    Haller N; Lutz TA
    Domest Anim Endocrinol; 2024 Oct; 89():106869. PubMed ID: 38870560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
    Nauck MA; Meier JJ
    Lancet Diabetes Endocrinol; 2016 Jun; 4(6):525-36. PubMed ID: 26876794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin hormones and beta cell function in chronic pancreatitis.
    Knop FK
    Dan Med Bull; 2010 Jul; 57(7):B4163. PubMed ID: 20591345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
    Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
    J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapies: where will we be 50 years from now?
    Meier JJ; Nauck MA
    Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.